Alberta Investment Management Corp decreased its position in shares of Chemed Co. (NYSE:CHE) by 6.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,900 shares of the company’s stock after selling 500 shares during the quarter. Alberta Investment Management Corp’s holdings in Chemed were worth $3,422,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. Harvest Fund Management Co. Ltd lifted its holdings in Chemed by 28.0% during the 1st quarter. Harvest Fund Management Co. Ltd now owns 462 shares of the company’s stock worth $200,000 after buying an additional 101 shares in the last quarter. Bank of America Corp DE lifted its holdings in Chemed by 9.9% during the 4th quarter. Bank of America Corp DE now owns 176,097 shares of the company’s stock worth $77,353,000 after buying an additional 15,808 shares in the last quarter. KBC Group NV acquired a new position in Chemed during the 4th quarter worth $2,560,000. Marshall Wace LLP acquired a new position in Chemed during the 4th quarter worth $1,715,000. Finally, Oppenheimer Asset Management Inc. lifted its holdings in Chemed by 0.4% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 18,870 shares of the company’s stock worth $8,289,000 after buying an additional 81 shares in the last quarter. 89.34% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts have issued reports on CHE shares. ValuEngine raised Chemed from a “sell” rating to a “hold” rating in a report on Tuesday, March 3rd. Royal Bank of Canada raised Chemed from a “sector perform” rating to an “outperform” rating and increased their price target for the company from $448.00 to $535.00 in a research note on Tuesday, March 10th. Oppenheimer increased their price target on Chemed from $525.00 to $535.00 and gave the company an “outperform” rating in a research note on Wednesday, February 19th. Finally, Zacks Investment Research raised Chemed from a “hold” rating to a “buy” rating and set a $489.00 price target on the stock in a research note on Tuesday. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Chemed currently has an average rating of “Buy” and an average target price of $509.80.
CHE stock opened at $477.21 on Friday. The business’s fifty day moving average is $440.95 and its 200-day moving average is $439.80. The company has a quick ratio of 0.78, a current ratio of 0.81 and a debt-to-equity ratio of 0.36. The company has a market cap of $7.58 billion, a P/E ratio of 34.14, a price-to-earnings-growth ratio of 2.98 and a beta of 0.67. Chemed Co. has a twelve month low of $324.31 and a twelve month high of $513.75.
Chemed (NYSE:CHE) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $3.68 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.65 by $0.03. The business had revenue of $515.80 million for the quarter, compared to the consensus estimate of $523.04 million. Chemed had a return on equity of 35.99% and a net margin of 11.60%. The firm’s revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the business posted $2.92 EPS. Research analysts anticipate that Chemed Co. will post 16.31 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 17th. Investors of record on Thursday, May 28th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.27%. The ex-dividend date of this dividend is Wednesday, May 27th. Chemed’s payout ratio is presently 9.18%.
In related news, VP Naomi C. Dallob sold 2,200 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $430.00, for a total transaction of $946,000.00. Following the sale, the vice president now owns 2,347 shares of the company’s stock, valued at approximately $1,009,210. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Donald E. Saunders sold 300 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $475.53, for a total value of $142,659.00. Following the sale, the director now directly owns 6,736 shares in the company, valued at approximately $3,203,170.08. The disclosure for this sale can be found here. Insiders have sold a total of 9,500 shares of company stock worth $4,108,179 in the last ninety days. 3.96% of the stock is currently owned by company insiders.
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations.
Read More: Limitations of analyzing profit margin
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.